Non-formulary cannabidiol (Epidiolex) will be covered on the prescription drug benefit when the following criteria are met:

Criteria for initial coverage (6 months)

- Prescribed by neurologist AND
- Age 2 years or older AND
- Prescribed for Dravet Syndrome or Lennox-Gastaut syndrome AND
- Refractory to at least 2 anti-epileptic drugs (AEDs) that are appropriate for diagnosis*; or patient has intolerance or contraindication AND
- No significant hepatic impairment (ALT or AST greater than 3 times upper limit of normal with bilirubin greater than 2 times upper limit of normal) AND
- Not using other cannabis or cannabis derivatives

Continued use criteria: Non-formulary cannabidiol (Epidiolex) will continue to be covered for 12 months on the prescription drug benefit when the following criteria are met:

- Continued to be prescribed by neurologist for Dravet Syndrome or Lennox-Gastaut syndrome AND
- Age 2 years or older AND
- Sustained improvement in seizure control (frequency and/or severity) since starting Epidiolex as assessed and documented by neurologist AND
- No significant hepatic impairment (ALT or AST greater than 3x upper limit of normal with bilirubin greater than 2 times upper limit of normal) AND
- Not using other cannabis or cannabis derivatives

* AEDs for Lennox Galtaut: felbamate, valproate, topiramate, lamotrigine, rufinamide, clobazam, clonazepam, zonisamide; AEDs for Dravet Syndrome: valproate, clobazam, levetiracetam, topiramate, zonisamide, clonazepam